The combination of Rapamycin and Dasatinib induced tumor regression in a genetic mouse mammary tumor virus-polyomer middle T antigen model [9], and in NSCLC suppressed Src and AKT phosphorylation [26]. This evidence concerns the gene SRC and non-small cell lung carcinoma.